Fluoresentric, Inc. Completes New Management Team, Raises Series B Funding

A-Team Takes Patented Technology Company in Bold Direction with New Investors

SALT LAKE CITY--()--Fluoresentric, Inc. today announced the completion of its new management team and closure of its Series B funding round. A small group of accredited investors have provided necessary funding to accelerate speed to market. Under the direction of company CEO William Olson, industry experts are now assembled to complete the company’s transition from successful polymerase chain reaction (PCR) assay design company to a start-up chemistry company positioned to monetize its disruptive XCR™ technology portfolio globally. The company will soon announce new XCR™ assays already in use by customers.

“To rapidly seize the greatest opportunity for stockholders and stakeholders, we clearly needed to build an A-Team to deliver the disruptive XCR™ technology portfolio globally,” states William Olson, CEO. “Years of research and development will now more quickly reach the greatest number of people who can benefit from faster, more reliable, and less costly genetic testing technology.”

Patented XCR™ is a novel nucleic acid amplification chemistry capable of tenfold faster results than PCR with superior resistance to classic PCR inhibitors. It works on existing PCR platforms, as well as on smaller, less costly instrumentation under development.

Joining CEO William Olson and Chief Science Officer and company founder Brian Caplin, Ph.D. on the Fluoresentric team is a lineup of experienced industry professionals:

Brian Hicke, Ph.D.—Chief Technology Officer—Dr. Hicke has 20 years’ experience in biotech R&D, emphasizing innovation, data-driven research and consensus-based leadership.

Wesley Lang, J.D.—Chief Patent Counsel—Wes has 12 years’ experience in drafting and prosecuting patents.

Mark Bagnall—Advisory Board Member—Mark has held senior management positions in the biotechnology industry for more than 20 years.

Juergen K. Flach, Ph.D.—Advisory Board Member—Dr. Flach has a 35 year background in leading positions in the Biotech / Life Science industry in the U.S. and Europe.

Bryson Green—Lab Director—Bryson 10 years in PCR methodology & assay optimization for DxNA & Fluoresentric.

AnnMarie Buoscio—Comptroller—AnnMarie has 11 years' experience delivering accounting services for companies in retail and investment. She has a B.S. in Accounting from St. Mary’s College.

The current standard for nucleic acid amplification requires 40 to 60 minutes, an unacceptable time for several critical testing areas, particularly at the Point of Care, where testing must be completed in less than 20 minutes to get a clinically actionable result. As a new approach to nucleic acid amplification testing (NAAT), XCR™ amplification and detection occurs in ~5 minutes with both DNA and RNA target nucleic acids. It eliminates amplification artifacts (e.g. primer-dimer) while dramatically reducing turnaround time, delivering a clinical result without compromise.

About Fluoresentric, Inc.

Fluoresentric Inc. is a start-up chemistry company positioned to monetize its XCR™ technology portfolio globally. Initially started as a custom PCR assay Design Company recruited by Roche to support their LightCycler® thermalcycler, the company has designed over 1,000 PCR assays. Fluoresentric scientists are internationally recognized experts in the field of Real Time Polymerase Chain Reaction (PCR). The company’s XCR™ technology is positioned to dramatically trim test times, and reduce healthcare costs, with a vision to deliver hyper-accurate molecular diagnostics testing at Point of Care.

*LightCycler® is a registered trademark of Roche

Contacts

PilmerPR
Danielle Durange, 704-350-5373
ddurange@pilmerpr.com

Release Summary

Fluoresentric, Inc. Completes New Management Team, Raises Series B Funding; A-Team Takes Patented Technology Company in Bold Direction with New Investors

Contacts

PilmerPR
Danielle Durange, 704-350-5373
ddurange@pilmerpr.com